Background: Ovarian tumor is the 2nd most common tumor of gynaecological origin. Its prognosis is weak due to allure presentation in the leading stages and the 5-year survival rate is <50% accompanying the available cures. So, there is a constant need for new organic markers. The friendship between HER2/neu overexpression and ovarian malignancy has been studied, but the results are still contentious. Therefore, this study was aimed at judging the association of HER2/neu accompanying the clinicopathological features of epithelial ovarian cancers (EOC).Objective(s):1. To evaluate HER2/neu over verbalization as a prognostic marker for epithelial ovarian tumor.2. To find out the partnership of HER-2/neu overexpression with chemotherapy reaction in epithelial ovarian cancer.Methodology: It was a anticipated study with a determinable correlational study design of 90 epithelial ovarian cancer (EOC) cases presenting to Fauji Foundation Hospital, Rawalpindi middle from two points Nov 2018 to Oct 2019. Immunohistochemistry (IHC) was applied for HER2/neu verbalization and IHC 3+ patients were considered HER2 beneficial. The association of HER2/neu accompanying clinicopathological factors of ovarian malignancy e.g. stage, grade, pretreatment CA-125 levels and with a destructive agent response were determined.Results: Mean age of diagnosis was 53 ± 8.022 age. Mean pre-treatment CA-125 level was 1262 ± 1683 and 81.1% (n=73) had raised pre-situation CA-125 levels.Most of the patients bestowed with state-of-the-art stage i.e. stage III (56.7%, n=51) and high grade that is grade III (54.4%, n=49). Most common histological type visualized was high grade serous malignant growth (51.1%). It was seen that 24.4% (n= 22) of the tumors over meant HER2/neu, 65.6% (n=59) were HER2/neu negative, whereas 10% (n=9) were uncertain for HER2/neu expression. Overall, 72.2% patients had light sensitive affliction. According to HER2/neu status, 20% HER2/neu definite patients had platinum delicate disease & 3.3% had opposing disease inasmuch as 47.8% HER2/neu negative patients had platinum impressionable disease & 10% were light resistant.There was a statistically significant partnership of HER2/neu expression accompanying grade (p 0.040) and pre-treatment CA-125 levels (p 0.032) inasmuch as our study failed to show significant union between stage (p 0.383) and a destructive agent response (p 0.055).Conclusion: Our study showed that, like other tumors, HER2/neu was positive in 24.4% victims and its union with grade & pre-situation CA-125 level was statistically significant, but we could not authenticate its union with a destructive agent response. However, this result needs to be ratified in a larger study society and patients need to be made inquiries for longer event to conduct survival reasonings so as to establish HER2/neu as a prognostic indicator for epithelial ovarian cancer.
Author(s) Details:
Sharmin Arif,
Department
of Oncology, Fauji Foundation Hospital, Rawalpindi, Pakistan.
Fauzia
Abdus Samad,
Department
of Oncology, Fauji Foundation Hospital, Rawalpindi, Pakistan.
Syed Abdus Samad,
Department of Oncology, Fauji Foundation Hospital, Rawalpindi,
Pakistan.
Anum Khan,
Department of Oncology, Fauji Foundation Hospital, Rawalpindi,
Pakistan.
Asif Riaz,
Department
of Oncology, Fauji Foundation Hospital, Rawalpindi, Pakistan.
Rimsha
Zahid,
Department
of Oncology, Fauji Foundation Hospital, Rawalpindi, Pakistan.
Please see the link here: https://stm.bookpi.org/NRAMMS-V2/article/view/11800
No comments:
Post a Comment